Tremfya (Guselkumab) Market By Product Type (Injectable Biologic); By Application (Plaque Psoriasis, Psoriatic Arthritis, Pipeline Indications – Crohn’s Disease, Ulcerative Colitis); By Distribution Channel (Hospital Pharmacies, Specialty Clinics, Retail & Specialty Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Tremfya Market is projected to expand consistently between 2024 and 2030, with an CAGR of 9.1%. The market is valued at USD 3.1 billion in 2024 and is expected to reach nearly USD 5.8 billion by 2030, according to Strategic Market Research.

 

Tremfya, developed by Janssen Pharmaceuticals under Johnson & Johnson, is the first selective IL-23p19 inhibitor approved for moderate-to-severe plaque psoriasis and psoriatic arthritis. Its mechanism of action offers a more targeted approach than earlier biologics, leading to higher treatment durability and reduced dosing frequency, which strengthens patient adherence.

 

Several macro forces are shaping the market between 2024 and 2030. Autoimmune disorders such as psoriasis are increasing globally, and biologics are steadily gaining adoption as frontline treatments over conventional systemic therapies. Regulatory agencies in major markets like the U.S., Europe, and Japan are approving new indications for Tremfya, widening its addressable patient base. At the same time, reimbursement reforms and payer alignment are creating broader access, especially in developed regions.

 

From a stakeholder perspective, pharmaceutical companies, healthcare providers, payers, regulators, and patient advocacy groups all influence the adoption landscape. Physicians are central to prescription decisions, while payers determine formulary placement and pricing access. Patient groups continue to push for better awareness and access to advanced biologics, particularly in underpenetrated markets across Asia and Latin America.

 

Tremfya is also strategically positioned within the competitive landscape. While it faces rivalry from other IL-23 inhibitors and oral small molecules, its unique dosing schedule and long-term safety data make it a strong choice for physicians seeking durable disease control. The brand’s growth trajectory will depend not only on Janssen’s commercial execution but also on how the biologics market evolves with biosimilar entries and new immunology innovations.

 

In short, Tremfya is more than a psoriasis therapy. It reflects the broader shift toward precision biologics in autoimmune care, where patient demand, regulatory support, and innovation are converging to reshape treatment pathways over the forecast period.

 

Market Segmentation And Forecast Scope

The Tremfya market can be segmented across multiple dimensions: product type, application, distribution channel, and geography. Each segment reflects how healthcare systems and prescribers adopt biologics within immunology.

By product type, Tremfya is primarily positioned as a biologic injectable therapy. Its differentiation comes from a subcutaneous formulation delivered every eight weeks after loading doses. This less frequent dosing is attractive compared to older biologics, which require more frequent administration. Pipeline developments are being monitored closely, but currently the injectable format remains the only commercialized version.

 

By application, the two core indications driving Tremfya’s market share are plaque psoriasis and psoriatic arthritis. Plaque psoriasis remains the larger segment, accounting for over half of Tremfya’s global use in 2024. Psoriatic arthritis is the second major driver, with adoption rising as rheumatologists increasingly shift to targeted biologics for patients with moderate to severe disease activity. Ongoing trials in Crohn’s disease and ulcerative colitis are expected to expand Tremfya’s application base later in the decade, which could diversify revenue streams and enhance its long-term positioning.

 

By distribution channel, Tremfya is dispensed mainly through hospital pharmacies, specialty pharmacies, and retail drug stores. Hospital and specialty pharmacies dominate in developed markets where biologics require tight handling and reimbursement coordination. Retail pharmacies are gaining share in markets with stronger specialty drug programs, while online pharmacy platforms are slowly emerging as a secondary channel in some regions, particularly in Asia-Pacific.

 

By region, the Tremfya market covers North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America leads due to high diagnosis rates, strong reimbursement, and specialist availability. Europe follows closely, supported by universal healthcare access and strong adoption in countries like Germany and the UK. Asia-Pacific is expected to record the fastest growth, driven by rising biologics adoption in Japan, South Korea, China, and India. Latin America and the Middle East and Africa remain smaller markets but are gaining traction as public and private healthcare systems expand their immunology drug portfolios.

 

Scope-wise, this segmentation demonstrates that Tremfya’s market growth is not only driven by its two primary indications but also by future opportunities in gastrointestinal diseases, expanding retail access points, and faster biologics penetration in emerging economies.

 

Market Trends And Innovation Landscape

The Tremfya market is evolving alongside broader shifts in the immunology and biologics landscape. Between 2024 and 2030, innovation is likely to center on three core areas: clinical expansion, technology-driven treatment support, and competitive differentiation.

 

One of the most prominent trends is the pursuit of broader indications. Tremfya is already established in plaque psoriasis and psoriatic arthritis, but ongoing clinical trials are evaluating its effectiveness in Crohn’s disease and ulcerative colitis. Success in these trials would not only open significant new patient populations but also allow Janssen to strengthen Tremfya’s position against other IL-23 inhibitors that are targeting similar gastrointestinal indications.

 

Another important development is the refinement of dosing regimens and patient adherence strategies. Tremfya already benefits from an every-eight-week schedule, which sets it apart from older biologics requiring more frequent injections. Companies are now investing in patient support programs, digital adherence tools, and at-home injection services. These tools are not just convenience features — they improve persistence rates, which in turn enhances the overall cost-effectiveness of biologics in payer evaluations.

 

From a technological standpoint, real-world evidence and digital health platforms are playing a bigger role in demonstrating value. Health systems and insurers are increasingly looking for long-term safety and efficacy data outside of controlled clinical trials. Janssen and competitors are investing in registries and AI-driven data platforms to track outcomes, adverse events, and cost savings across diverse patient populations. This trend is likely to influence formulary placement and reimbursement discussions in the coming years.

 

Competition within the IL-23 class is also driving innovation. Rivals such as risankizumab and tildrakizumab are pushing the boundaries with differentiated positioning. Skyrizi , for example, has aggressively pursued multiple indications, creating a race for label breadth. This competitive environment forces Tremfya’s lifecycle strategy to remain agile, balancing incremental improvements with bold expansion moves.

 

Another trend worth noting is the growing acceptance of biosimilars in immunology. While Tremfya itself does not yet face biosimilar competition, the entry of biosimilars for older biologics like Humira has reshaped payer expectations. The long-term implication is that even premium biologics such as Tremfya will eventually need to justify their cost with superior durability, broader indications, or bundled patient services.

 

In summary, the innovation landscape for Tremfya is shaped by more than clinical trial data. It now includes adherence technologies, real-world data, and payer-driven economics. These trends suggest that Janssen’s ability to integrate science with patient experience and payer priorities will determine Tremfya’s trajectory through 2030.

 

Competitive Intelligence And Benchmarking

The Tremfya market sits within a highly competitive biologics class, where innovation and speed to indication expansion are key determinants of market share. Janssen Pharmaceuticals, through its parent Johnson & Johnson, holds the commercial rights to Tremfya and has built a strong positioning strategy based on differentiated dosing, durable response rates, and expanding clinical evidence.

 

Benchmarking Tremfya against other IL-23 inhibitors reveals both strengths and vulnerabilities. Skyrizi , marketed by AbbVie, is the most formidable competitor. It has gained rapid adoption due to aggressive clinical expansion, particularly in Crohn’s disease and ulcerative colitis. Skyrizi’s multi-indication strategy gives it broader physician visibility across specialties, making it a benchmark for market penetration. In contrast, Tremfya’s current approvals remain limited to psoriasis and psoriatic arthritis, though ongoing trials could help narrow this gap.

 

Ilumya , developed by Sun Pharma, represents another player in the IL-23 space. While Ilumya’s adoption has been more modest, it competes on pricing and accessibility in certain markets, particularly in Asia-Pacific. This pricing dynamic highlights a pressure point for Tremfya as payers continue to weigh efficacy against cost, especially in emerging regions.

 

Stelara, Janssen’s own IL-12/23 inhibitor, still holds a notable market presence, especially in gastrointestinal diseases. However, Janssen is carefully managing the transition from Stelara to Tremfya, aiming to move patients toward the more selective IL-23 mechanism that aligns with future growth. This internal portfolio balancing act is critical for Johnson & Johnson to defend overall market share against external competitors.

 

Beyond IL-23 inhibitors, the competitive field includes IL-17 blockers such as secukinumab (Novartis) and ixekizumab (Eli Lilly), as well as TNF inhibitors that remain entrenched in some treatment pathways. Although these drugs represent older classes, they continue to hold formulary positions, often as first-line biologics due to lower costs and long-standing safety records. Tremfya must therefore compete not only within its immediate class but also across adjacent biologics with entrenched market access.

 

Strategically, Janssen’s approach centers on lifecycle management. This includes broadening Tremfya’s indications, investing in long-term safety data, and strengthening payer partnerships. At the same time, competitor strategies focus on expanding market share through aggressive pricing, broader indication portfolios, and enhanced patient support programs.

 

The competitive intelligence picture underscores a fundamental reality: Tremfya has strong differentiation today, but maintaining leadership requires constant adaptation. Its benchmarking against AbbVie’s Skyrizi , Sun Pharma’s Ilumya , and legacy biologics like Stelara shows both the opportunity and the urgency of expanding its therapeutic footprint before biosimilars and new mechanisms disrupt the landscape further.

 

Regional Landscape And Adoption Outlook

The adoption of Tremfya varies significantly across regions, shaped by healthcare infrastructure, reimbursement systems, physician practices, and patient awareness. Between 2024 and 2030, regional dynamics will define where growth accelerates fastest and where barriers remain.

In North America, Tremfya has established a leading presence, with the United States accounting for the largest share of prescriptions. High psoriasis prevalence, strong specialist networks, and favorable reimbursement policies underpin adoption. The presence of established specialty pharmacy channels and patient assistance programs further supports adherence. In Canada, public health coverage has expanded biologic access, though cost-containment pressures remain. North America will likely continue to hold the largest share of the Tremfya market through 2030, driven by both psoriasis and psoriatic arthritis patients.

 

Europe is another stronghold, particularly in Germany, the UK, and the Nordics, where biologics adoption is well integrated into standard treatment pathways. The European Medicines Agency has provided regulatory momentum with label expansions, while national health systems are gradually widening reimbursement. However, budget constraints and increasing pressure to evaluate cost-effectiveness mean that Tremfya competes closely with other IL-23 inhibitors and older biologics that remain in formularies. Southern and Eastern Europe lag somewhat in adoption due to more limited funding and slower guideline updates.

 

Asia-Pacific is expected to record the fastest growth. Countries like Japan and South Korea are early adopters of advanced biologics, with streamlined reimbursement frameworks and strong physician confidence. China and India, with their large psoriasis patient bases, are beginning to scale up biologics access as healthcare infrastructure expands. However, affordability remains a challenge in many parts of the region, and payer negotiations will play a decisive role in future uptake. Partnerships with local distributors and governments will be essential for Janssen to expand Tremfya’s footprint here.

 

Latin America is showing gradual adoption, with Brazil and Mexico leading regional demand. In these markets, public-private partnerships and specialty programs are enabling access to biologics, though out-of-pocket costs remain high for many patients. Argentina and Colombia also offer opportunities, but regulatory and pricing complexities can delay widespread adoption.

 

The Middle East and Africa currently represent the smallest share of the market. Wealthier Gulf countries, particularly Saudi Arabia and the UAE, are introducing Tremfya into advanced hospital networks, but broader adoption across Africa is constrained by infrastructure gaps and limited reimbursement capacity. Over time, donor-funded programs and collaborations with private hospitals may open growth opportunities in underserved populations.

 

Overall, regional analysis highlights a two-speed market. North America and Europe remain the most mature with entrenched adoption, while Asia-Pacific and Latin America offer higher growth rates due to expanding healthcare access. For Tremfya to maximize its global footprint, Janssen must balance defending share in established regions with aggressively pursuing white space in emerging markets.

 

End-User Dynamics And Use Case

Tremfya adoption is shaped by the types of healthcare providers that prescribe and manage biologic therapies. Each end-user group approaches the drug differently, based on patient volume, treatment protocols, and financial considerations.

Hospital pharmacies remain the most common dispensing point in developed markets. Large hospitals with dermatology and rheumatology departments typically handle biologic prescriptions, supported by in-house specialty pharmacies that coordinate prior authorizations and patient monitoring. These institutions value Tremfya’s long dosing interval, which reduces patient visits and administrative burden compared to older biologics.

 

Specialty clinics, particularly dermatology and rheumatology practices, play a central role in adoption. In the U.S. and parts of Europe, independent specialist clinics account for a significant share of prescriptions. These providers are often early adopters of new therapies, guided by clinical trial evidence and updated guidelines. Their prescribing decisions are heavily influenced by payer formularies but also by the perceived ease of patient adherence. Tremfya’s every-eight-week schedule and strong safety profile are appealing in this context.

 

Retail and specialty pharmacies are increasingly important in distribution, especially in markets where patient access is shifting outside of hospital systems. Programs that enable home delivery and nurse-assisted at-home injections are gaining traction. This shift reflects a broader healthcare trend of decentralizing specialty drug delivery to improve patient convenience and reduce system costs.

 

Ambulatory surgical centers play a smaller role, but in cases where biologics are started in perioperative settings, they may contribute to initiation volumes. However, ongoing maintenance therapy generally transitions to hospitals or outpatient clinics.

 

A practical use case illustrates these dynamics. In a U.S. community dermatology clinic, physicians introduced Tremfya as a second-line option for patients who had not responded well to topical treatments or older biologics. The clinic integrated a digital patient support platform that reminded patients of injection schedules and tracked symptom improvements. Within one year , patient adherence improved by nearly 20 percent, and the clinic reported fewer treatment interruptions. This not only improved patient outcomes but also reduced payer disputes over therapy persistence.

 

These examples show that Tremfya’s value is experienced differently across end-user segments. Hospitals prioritize streamlined administration, specialty clinics focus on clinical effectiveness and patient adherence, and pharmacies emphasize logistics and affordability. For Janssen, aligning engagement strategies with each end-user group will remain essential to sustaining Tremfya’s competitive position.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• In 2023, Janssen secured expanded FDA approval for Tremfya in active psoriatic arthritis, strengthening its positioning in rheumatology.

• Phase III trial data released in 2023 showed promising results for Tremfya in Crohn’s disease, signaling potential entry into gastrointestinal indications.

• In 2024, the European Medicines Agency updated its label to include new long-term safety data, which supported broader use in plaque psoriasis patients.

• Janssen has expanded patient access programs across North America and Europe, focusing on co-pay assistance and digital adherence platforms.

 

Opportunities

• Expanding indications into Crohn’s disease and ulcerative colitis could open significant new patient populations and diversify revenue.

• Rising biologics adoption in Asia-Pacific and Latin America offers growth potential as healthcare access and reimbursement frameworks improve.

• Increasing reliance on real-world evidence and digital monitoring platforms creates opportunities to strengthen payer negotiations and demonstrate long-term cost-effectiveness.

 

Restraints

• Intense competition from other IL-23 inhibitors such as risankizumab and tildrakizumab, as well as IL-17 and TNF inhibitors that remain entrenched in formularies.

• Pricing pressures from payers and governments, especially as biosimilars of older biologics reset expectations for cost-effectiveness.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 3.1 Billion
Revenue Forecast in 2030	USD 5.8 Billion
Overall Growth Rate	CAGR of 9.1% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By Distribution Channel, By Geography
By Product Type	Injectable Biologic (subcutaneous)
By Application	Plaque Psoriasis, Psoriatic Arthritis, Pipeline (Crohn’s, Ulcerative Colitis – under study)
By Distribution Channel	Hospital Pharmacies, Specialty Clinics, Retail & Specialty Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, China, India, Japan, Brazil, Saudi Arabia, South Africa
Market Drivers	Growing autoimmune disease burden; Expanding biologics reimbursement; Advancements in IL-23 inhibitor pipeline
Customization Option	Available upon request